Hematology NewsFDA approves elotuzumab with pom/dex in refractory myelomaNovember 7, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Oncology PracticeFDA approves lorlatinib as second line for ALK-positive advanced NSCLCNovember 5, 2018Lung Cancer
Hematology NewsOMS721 gains orphan designation for HSCT-associated thrombotic microangiopathyOctober 26, 2018Transfusion MedicineThrombosis
Hematology NewsIbrutinib plus obinutuzumab gets priority review in CLL/SLLOctober 17, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, TransplantationImmuno-oncology
Oncology PracticeTalazoparib approved for HER2-negative advanced breast cancerOctober 16, 2018Breast Cancer
Hematology NewsFDA offers guidance on MRD assessment in blood cancer trialsOctober 16, 2018Business of MedicineMultiple MyelomaPractice ManagementLeukemia, Myelodysplasia, Transplantation
Hematology NewsFDA approves DNA-based blood type testOctober 12, 2018Transfusion MedicineAnemiaBleeding Disorders
Hematology NewsRivaroxaban gains indication for prevention of major cardiovascular events in CAD/PADOctober 12, 2018Thrombosis
Hematology NewsFDA approves emicizumab for hemophilia A without inhibitorsOctober 4, 2018Bleeding Disorders
Oncology PracticeFDA approves cemiplimab for advanced cutaneous squamous cell carcinomaSeptember 29, 2018Nonmelanoma Skin Cancer
Hematology NewsFDA approves new drug for CLL/SLL and follicular lymphomaSeptember 25, 2018CLLIndolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
